Search
for

    Glossary Nasopharyngitis

    inflammation of nasal passages and throat, often called common cold

    Nasopharyngitis, commonly known as the common cold, is an inflammation of the nasal passages and the pharynx (throat) typically caused by viral infections such as rhinoviruses. Symptoms often include a runny nose, sore throat, cough, and congestion, and while it is usually mild and self-limiting, it can be particularly troublesome for individuals with weakened immune systems.

    Research 10 of 140

    1. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials 2022 · 25 citations
    2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) American Journal of Clinical Dermatology · 2023 · 20 citations
    3. Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial The Journal of Dermatology · 2025 · 4 citations
    4. 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis Journal of Investigative Dermatology · 2019 · 1 citations
    5. ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW International Journal of Innovative Technologies in Social Science · 2025
    6. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    7. EPH39 Alopecia Areata: Targeted Review of Adverse Events Associated with Clinical Studies of Treatments Value in Health · 2023
    8. Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program SKIN The Journal of Cutaneous Medicine · 2025
    9. Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial Pediatric Dermatology · 2023 · 48 citations
    10. Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials SKIN The Journal of Cutaneous Medicine · 2025
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →